Azithromycin
Small molecule targets APC, CYP3A4, MTOR via restoration / inhibition
Regulatory milestones approvals, filings & regulatory actions · 11 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | ZMAX | — | 2008-10-07 | fda.gov ↗ |
| Label expansions (5) | US (FDA) | ZITHROMAX | — | 1996-11-22 – 2004-01-15 | fda.gov ↗ |
| Label expansions (4) | US (FDA) | BICILLIN L-A | — | 1954-10-21 – 1982-09-16 | fda.gov ↗ |
| Approved | US (FDA) | BICILLIN L-A | — | 1952-06-27 | fda.gov ↗ |
Trials 386 · started per year
Also used as a comparator or background therapy in 200 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT02099240 Comparator | Mar 2014 → Nov 2018 | osteomyelitis | University of Louisville | Terminated | No outcome recorded |
| Phase 112 trials | ||||||
| Phase 1 | NCT06543290 Comparator | Aug 2023 → Aug 2026 overdue | infectious disease | Arrowhead Regional Medical Center | Recruiting | No outcome recorded |
| Phase 1 | NCT04457609 Background | Jul → Aug 2020 | COVID-19, pneumonia | Indonesia University | Unknown | No outcome recorded |
| Phase 1 | NCT04280406 Comparator | Feb 2020 → Dec 2023 | — | University of Montreal | Unknown | No outcome recorded |
| Phase 1 | NCT05437783 Comparator | Jan 2020 → Jul 2022 | — | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | Unknown | No outcome recorded |
| Phase 1 | NCT02527005 Comparator | Sep 2015 → Aug 2016 | HIV infectious disease, malaria | University of Ibadan | Completed | No outcome recorded |
| Phase 1 | NCT04870138 Background | Mar 2013 → Apr 2015 | gonorrhea | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT01416350 Comparator | Mar → May 2011 | autoimmune disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01169038 Comparator | Jul → Nov 2010 | pulmonary sarcoidosis | Vanderbilt University | Completed | No outcome recorded |
| Phase 1 | NCT01201577 Comparator | Oct 2009 → May 2011 | infectious disease with sepsis | University of Nottingham | Completed | No outcome recorded |
| Phase 1 | NCT00844207 Comparator | Feb → Apr 2009 | malaria | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00830206 Comparator | Jan 2006 | — | Teva Pharmaceuticals USA | Completed | No outcome recorded |
| Phase 1 | NCT00865670 Comparator | Aug → Sep 2003 | infectious disease | Sandoz | Completed | No outcome recorded |
| Phase 1/26 trials | ||||||
| Phase 1/2 | NCT06921525 Comparator | Apr → Jul 2025 overdue | dry eye syndrome | Ehab Mohamed Elsayed Mohamed Saad | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT04591600 Background | Jul → Sep 2020 | COVID-19 | Alkarkh Health Directorate-Baghdad | Completed | No outcome recorded |
| Phase 1/2 | NCT04461925 Background | May 2020 → May 2021 | pneumonia | Institute of Cell Therapy | Unknown | No outcome recorded |
| Phase 1/2 | NCT04390152 Comparator | Jan 2020 → Mar 2022 | acute respiratory distress syndrome | BioXcellerator | Terminated | No outcome recorded |
| Phase 1/2 | NCT03502356 Comparator | Apr → Jun 2018 | — | Ain Shams University | Unknown | No outcome recorded |
| Phase 1/2 | NCT02960503 Comparator | Sep 2016 → Oct 2018 | sickle cell disease | Vanderbilt University | Withdrawn | No outcome recorded |
| Phase 234 trials | ||||||
| Phase 2 | NCT06488781 Comparator | Apr 2025 → Dec 2028 expected | pregnancy disorder | University of Oklahoma | Recruiting | No outcome recorded |
| Phase 2 | NCT05922761 Background | May 2024 → Jun 2027 expected | chronic graft versus host disease, transplant-related bronchiolitis obliterans | Dana-Farber Cancer Institute | Recruiting | No outcome recorded |
| Phase 2 | NCT05028153 Comparator | Nov 2022 → Nov 2026 expected | acute asthma | Copenhagen Studies on Asthma in Childhood | Recruiting | No outcome recorded |
| Phase 2 | NCT05121974 Comparator | Aug 2022 → Mar 2025 overdue | shigellosis | International Centre for Diarrhoeal Disease Research, Bangladesh | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05461131 Background | Jun 2022 → Jul 2023 | pertussis | ILiAD Biotechnologies | Completed | No outcome recorded |
| Phase 2 | NCT04294641 Background | May 2021 → Jun 2024 | chronic graft versus host disease | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT04553406 Comparator | Dec 2020 → Jan 2021 | Mycobacterium avium complex disease, pulmonary non-tuberculous mycobacterial infection | Spero Therapeutics | Terminated | No outcome recorded |
| Phase 2 | NCT05398965 Background | Nov 2020 → Jan 2021 | COVID-19 | Hasanuddin University | Completed | No outcome recorded |
| Phase 2 | NCT04459702 Background | Jul 2020 → Jul 2021 | COVID-19, severe acute respiratory syndrome | ProgenaBiome | Withdrawn | No outcome recorded |
| Phase 2 | NCT04501965 Background | Jun → Aug 2020 | COVID-19 | Institute for Research and Development of Medicinal and Food Plants of Guinea | Unknown | No outcome recorded |
| Phase 2 | NCT04502342 Background | Jun → Aug 2020 | COVID-19 | Institute for Research and Development of Medicinal and Food Plants of Guinea | Unknown | No outcome recorded |
| Phase 2 | NCT04374539 Comparator | Apr 2020 → Jun 2021 | COVID-19 | Fundacion Clinic per a la Recerca Biomédica | Terminated | No outcome recorded |
| Phase 2 | NCT04369365 Comparator | Apr 2020 → Jun 2021 | COVID-19 | Prof. Dr. Matthias Preusser | Completed | No outcome recorded |
| Phase 2 | NCT04322396 Comparator | Apr 2020 → Feb 2021 | COVID-19 | Chronic Obstructive Pulmonary Disease Trial Network, Denmark | Terminated | No outcome recorded |
| Phase 2 | NCT04332094 Background | Apr 2020 → Jun 2021 | COVID-19 | Sant Pau Research Institute | Unknown | No outcome recorded |
| Phase 2 | NCT04329832 Comparator | Mar → Jul 2020 | COVID-19 | Intermountain Health Care, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT04366089 Background | Mar → Oct 2020 | COVID-19, viral pneumonia | Roberto Poscia MD, PhD | Unknown | No outcome recorded |
| Phase 2 | NCT04150250 Background | Nov 2019 → Jul 2020 | cholera | PATH | Completed | No outcome recorded |
| Phase 2 | NCT03736629 Comparator | Feb 2019 → Mar 2021 | chronic asthma | University of Chicago | Terminated | No outcome recorded |
| Phase 2 | NCT03618108 Comparator | Apr 2018 → Nov 2020 | chlamydia infectious disease, coronary atherosclerosis | Cadrock Pty. Ltd. | Terminated | No outcome recorded |
| Phase 2 | NCT03431168 Comparator | Mar 2018 → Jan 2021 | HIV infectious disease, malaria | University of Alabama at Birmingham | Completed | No outcome recorded |
| Phase 2 | NCT02707523 Comparator | Jan 2016 → Feb 2019 | respiratory syncytial virus infectious disease | University of Alabama at Birmingham | Completed | No outcome recorded |
| Phase 2 | NCT02517099 Comparator | Jun 2015 → Aug 2018 | asthma | Imperial College London | Completed | No outcome recorded |
| Phase 2 | NCT02024555 Comparator | Mar 2014 → Apr 2019 | sarcoidosis | Vanderbilt University | Completed | No outcome recorded |
| Phase 2 | NCT01769027 Comparator | Jun → Dec 2013 | — | CNS Onlus | Withdrawn | No outcome recorded |
| Phase 2 | NCT01448993 Comparator | Aug 2012 → Jan 2015 | dyskinesia of esophagus | JAFAR JAFARI | Completed | No outcome recorded |
| Phase 2 | NCT01631201 Comparator | Jul 2012 → Mar 2013 | chlamydia trachomatis infectious disease | ActivBiotics Pharma, LLC | Completed | No outcome recorded |
| Phase 2 | NCT01617083 Comparator | May 2012 → Dec 2014 | obsessive-compulsive disorder, pediatric acute-onset neuropsychiatric syndrome | University of South Florida | Completed | No outcome recorded |
| Phase 2 | NCT01486758 Comparator | Dec 2011 → Apr 2014 | respiratory syncytial virus bronchiolitis | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 2 | NCT01233297 Comparator | Nov 2010 → Oct 2027 expected | childhood onset asthma | Copenhagen Studies on Asthma in Childhood | Active not recruiting | No outcome recorded |
| Phase 2 | NCT00796224 Comparator | Dec 2008 → Feb 2009 | otitis media | Pfizer | Completed | No outcome recorded |
| Phase 2 | NCT00427609 Comparator | Jan 2007 → Nov 2009 | psoriasis | University of Tennessee | Terminated | No outcome recorded |
| Phase 2 | NCT00298922 Comparator | Feb 2006 → Feb 2009 | cystic fibrosis | Unity Health Toronto | Unknown | No outcome recorded |
| Phase 2 | NCT00319956 Comparator | Sep 2004 → Jun 2012 | bronchopulmonary dysplasia | Hubert Ballard | Completed | No outcome recorded |
| Phase 2/38 trials | ||||||
| Phase 2/3 | NCT05972772 Comparator | Nov 2024 → Aug 2025 overdue | infectious disease | Lao-Oxford-Mahosot Hospital Wellcome Trust Research Unit | Recruiting | No outcome recorded |
| Phase 2/3 | NCT04395170 Background | Sep → Dec 2020 | COVID-19 | Lifefactors Zona Franca, SAS | Unknown | No outcome recorded |
| Phase 2/3 | NCT04729491 Comparator | Jun → Sep 2020 | COVID-19 | Corpometria Institute | Completed | No outcome recorded |
| Phase 2/3 | NCT04347031 Background | Apr → Nov 2020 | respiratory failure, viral pneumonia | Burnasyan Federal Medical Biophysical Center | Completed | No outcome recorded |
| Phase 2/3 | NCT03672630 Comparator | Feb 2019 → Jan 2026 | Mycobacterium avium complex disease, pulmonary non-tuberculous mycobacterial infection | Kevin Winthrop | Completed | No outcome recorded |
| Phase 2/3 | NCT02911935 Comparator | Nov 2016 → Apr 2021 | respiratory syncytial virus bronchiolitis | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 2/3 | NCT02605122 Comparator | Apr 2016 → Mar 2018 | bacterial pneumonia | Melinta Therapeutics, Inc. | Terminated | No outcome recorded |
| Phase 2/3 | NCT01348321 Background | Nov 2008 → Oct 2009 | acne | Ahvaz Jundishapur University of Medical Sciences | Completed | No outcome recorded |
| Phase 342 trials | ||||||
| Phase 3 | NCT06409299 Comparator | Sep 2024 → Mar 2027 expected | bronchiectasis, bronchopulmonary dysplasia, cystic disease of lung, respiratory or thoracic malformation | Rigshospitalet, Denmark | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06273891 Comparator | Mar 2024 → May 2026 overdue | preterm premature rupture of the membranes | Inova Health Care Services | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06082037 Background | Oct 2023 → Jan 2029 expected | transplant rejection | Sanofi | Recruiting | No outcome recorded |
| Phase 3 | NCT05894954 Background | Jul 2023 → Oct 2025 | cognitive impairment with or without cerebellar ataxia, dementia | Alzheimer's Prevention and Reversal Project, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT05764876 Comparator | Mar 2023 → Jun 2024 | ulcer disease, yaws | Fight AIDS and Infectious Diseases Foundation | Completed | No outcome recorded |
| Phase 3 | NCT04669288 Comparator | Nov 2021 → Dec 2024 | asthma | University of Arizona | Terminated | No outcome recorded |
| Phase 3 | NCT04677569 Background | Apr 2021 → Nov 2025 | pulmonary non-tuberculous mycobacterial infection | Insmed Incorporated | Completed | No outcome recorded |
| Phase 3 | NCT04235816 Comparator | Mar 2021 → Sep 2025 overdue | — | Barcelona Institute for Global Health | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05026801 Comparator | Feb → Aug 2021 | viral respiratory tract infection | Iterum Therapeutics, International Limited | Withdrawn | No outcome recorded |
| Phase 3 | NCT04677543 Comparator | Dec 2020 → May 2023 | Mycobacterium avium complex disease | Insmed Incorporated | Completed | No outcome recorded |
| Phase 3 | NCT04673214 Comparator | Dec 2020 → Feb 2021 | COVID-19 | Gilberto Cruz Arteaga | Completed | No outcome recorded |
| Phase 3 | NCT04424511 Comparator | Oct 2020 → Dec 2024 | — | Tampere University | Completed | No outcome recorded |
| Phase 3 | NCT04613271 Comparator | Oct 2020 → Oct 2021 | COVID-19 | Ina-Respond | Completed | No outcome recorded |
| Phase 3 | NCT04383717 Comparator | May → Aug 2020 | respiratory tract infectious disorder | Cairo University | Unknown | No outcome recorded |
| Phase 3 | NCT04363203 Comparator | Apr 2020 → Mar 2021 | COVID-19 | Salomeh Keyhani MD | Suspended | No outcome recorded |
| Phase 3 | NCT04344379 Comparator | Apr → Jun 2020 | COVID-19 | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 3 | NCT04355052 Comparator | Apr → Oct 2020 | COVID-19 | Sheba Medical Center | Unknown | No outcome recorded |
| Phase 3 | NCT04341727 Comparator | Apr 2020 → Apr 2021 | COVID-19 | Washington University School of Medicine | Terminated | No outcome recorded |
| Phase 3 | NCT04334382 Comparator | Apr → Dec 2020 | COVID-19 | Intermountain Health Care, Inc. | Unknown | No outcome recorded |
| Phase 3 | NCT04328272 Comparator | Mar → May 2020 | COVID-19 | Prof. Dr. Umar Farooq | Unknown | No outcome recorded |
| Phase 3 | NCT04381936 Comparator | Mar 2020 → Sep 2028 expected | pneumonia | University of Oxford | Recruiting | No outcome recorded |
| Phase 3 | NCT04069312 Comparator | Feb 2020 → Mar 2026 | chronic bronchitis | Johns Hopkins University | Completed | No outcome recorded |
| Phase 3 | NCT03959527 Comparator | Nov 2019 → Aug 2023 | gonorrhea | Global Antibiotics Research and Development Partnership | Completed | No outcome recorded |
| Phase 3 | NCT04010539 Comparator | Oct 2019 → Oct 2023 | gonorrhea | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT03657342 Comparator | Mar 2019 → Apr 2024 | chronic transplant rejection, transplant-related bronchiolitis obliterans | Zambon SpA | Completed | No outcome recorded |
| Phase 3 | NCT03474276 Comparator | Jan → Dec 2018 | protein-energy malnutrition | Institut Pasteur | Completed | No outcome recorded |
| Phase 3 | NCT02426112 Comparator | Jun 2016 → Sep 2018 | HIV infectious disease, lung disorder | London School of Hygiene and Tropical Medicine | Completed | No outcome recorded |
| Phase 3 | NCT02773407 Comparator | May 2016 → Aug 2019 | unexplained long-lasting fever/inflammatory syndrome | Oxford University Clinical Research Unit, Vietnam | Completed | No outcome recorded |
| Phase 3 | NCT02269644 Background | Nov 2015 → Nov 2016 | — | Durata Therapeutics Inc., an affiliate of Allergan plc | Withdrawn | No outcome recorded |
| Phase 3 | NCT02210325 Comparator | Aug 2014 → Feb 2017 | gonorrhea | Melinta Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT02054156 Comparator | Jun 2014 → Aug 2018 | cystic fibrosis | Bonnie Ramsey | Completed | No outcome recorded |
| Phase 3 | NCT01531218 Comparator | Mar 2012 → Dec 2013 | diarrheal disease | University of Aarhus | Completed | No outcome recorded |
| Phase 3 | NCT01398072 Comparator | Dec 2011 → Jan 2013 | chronic obstructive pulmonary disease | University College, London | Unknown | No outcome recorded |
| Phase 3 | NCT01102244 Comparator | Apr → Jun 2010 | blepharitis | Alcon Research | Completed | No outcome recorded |
| Phase 3 | NCT00415350 Comparator | Apr 2008 → Dec 2009 | bronchiectasis | W.G.Boersma | Completed | No outcome recorded |
| Phase 3 | NCT00717561 Comparator | Feb 2008 → May 2009 | pneumonia | Bayer | Completed | No outcome recorded |
| Phase 3 | NCT00741052 Comparator | Jul 2007 → Oct 2008 | cholera | International Centre for Diarrhoeal Disease Research, Bangladesh | Completed | No outcome recorded |
| Phase 3 | NCT00358462 Comparator | Jan 2007 → Nov 2011 | urethritis | University of Washington | Completed | No outcome recorded |
| Phase 3 | NCT00351273 Comparator | May 2006 → Sep 2008 | reactive arthritis | University of South Florida | Completed | No outcome recorded |
| Phase 3 | NCT00648726 Comparator | Jan → Aug 2003 | pneumonia | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00649831 Comparator | Oct 2002 → Jun 2003 | chronic bronchitis | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00754949 Comparator | — | blepharoconjunctivitis | Sun Pharmaceutical Industries, Inc. | Withdrawn | No outcome recorded |
| Phase 465 trials | ||||||
| Phase 4 | NCT05763693 Comparator | Apr 2026 → Apr 2030 expected | infectious disease, nutritional deficiency disease | University of California, San Francisco | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07306234 Comparator | Mar 2026 → Jan 2029 expected | Mycoplasma pneumoniae pneumonia | Young June Choe | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06468462 Comparator | Oct 2025 → Oct 2028 expected | gonorrhea, syphilis | University of Washington | Recruiting | No outcome recorded |
| Phase 4 | NCT07384793 Comparator | Oct 2025 → Apr 2026 overdue | acne | Hayatabad Medical Complex | Active not recruiting | No outcome recorded |
| Phase 4 | NCT07164131 Comparator | Sep 2025 → Sep 2030 expected | pneumonia | Mayo Clinic | Recruiting | No outcome recorded |
| Phase 4 | NCT07183462 Comparator | Sep 2025 → Jun 2029 expected | pregnancy disorder, preterm premature rupture of the membranes | Sheba Medical Center | Recruiting | No outcome recorded |
| Phase 4 | NCT07052942 Comparator | Aug 2025 → Nov 2029 expected | acute asthma | DARTNet Institute | Recruiting | No outcome recorded |
| Phase 4 | NCT07084402 Background | Jul 2025 → Jul 2027 expected | Mycobacterium avium complex disease | Bin Cao | Recruiting | No outcome recorded |
| Phase 4 | NCT07213765 Comparator | Jul 2025 → Sep 2028 expected | Mycobacterium avium complex disease | Bin Cao | Recruiting | No outcome recorded |
| Phase 4 | NCT06715150 Comparator | Jan 2025 → Jan 2026 overdue | periodontal disorder | University of Santiago de Compostela | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06584474 Comparator | Oct 2024 → Jun 2025 | bronchopulmonary dysplasia | Alexandria University | Completed | No outcome recorded |
| Phase 4 | NCT06289647 Comparator | Oct 2024 → Aug 2029 | trachoma | University of California, San Francisco | Withdrawn | No outcome recorded |
| Phase 4 | NCT06358872 Comparator | Apr 2024 → Apr 2028 expected | — | University of California, San Francisco | Recruiting | No outcome recorded |
| Phase 4 | NCT06272370 Comparator | Feb → Sep 2024 | asthma, hypersensitivity reaction disease, obstructive lung disease, respiratory tract infectious disorder | DARTNet Institute | Completed | No outcome recorded |
| Phase 4 | NCT05288023 Comparator | Dec 2022 → Jan 2024 | primary bacterial infectious disease | University of California, San Francisco | Terminated | No outcome recorded |
| Phase 4 | NCT05677282 Comparator | Oct 2022 → Sep 2025 overdue | acute diarrhea | Henry M. Jackson Foundation for the Advancement of Military Medicine | Recruiting | No outcome recorded |
| Phase 4 | NCT05027516 Comparator | Jan → May 2022 | gonorrhea | Institute of Tropical Medicine, Belgium | Completed | No outcome recorded |
| Phase 4 | NCT03570814 Comparator | Dec 2021 → Feb 2022 | filariasis, trachoma | London School of Hygiene and Tropical Medicine | Completed | No outcome recorded |
| Phase 4 | NCT04716712 Comparator | Oct 2021 → Jan 2025 overdue | — | University of California, San Francisco | Active not recruiting | No outcome recorded |
| Phase 4 | NCT04669717 Comparator | Sep 2021 → Dec 2028 expected | periodontitis | University of Geneva, Switzerland | Recruiting | No outcome recorded |
| Phase 4 | NCT04774991 Comparator | Jun 2021 → Jun 2023 | — | University of California, San Francisco | Completed | No outcome recorded |
| Phase 4 | NCT04185402 Comparator | May 2021 → Dec 2024 | trachoma | University of California, San Francisco | Completed | No outcome recorded |
| Phase 4 | NCT04349826 Comparator | May 2021 → Dec 2025 | typhoid fever | Oxford University Clinical Research Unit, Vietnam | Completed | No outcome recorded |
| Phase 4 | NCT04921943 Comparator | May 2021 → Dec 2025 overdue | pulmonary non-tuberculous mycobacterial infection | Oregon Health and Science University | Recruiting | No outcome recorded |
| Phase 4 | NCT06090565 Comparator | Apr 2021 → Jun 2022 | gonorrhea | Bulovka Hospital | Completed | No outcome recorded |
| Phase 4 | NCT05118984 Comparator | Feb → May 2021 | endometritis | Cairo University | Completed | No outcome recorded |
| Phase 4 | NCT04224987 Comparator | Nov 2020 → Jul 2024 | primary bacterial infectious disease | University of California, San Francisco | Completed | No outcome recorded |
| Phase 4 | NCT04294069 Comparator | Sep → Dec 2020 | preterm premature rupture of the membranes | Thomas Jefferson University | Completed | No outcome recorded |
| Phase 4 | NCT04315272 Comparator | Aug 2020 → Jun 2022 | malaria | University of California, San Francisco | Completed | No outcome recorded |
| Phase 4 | NCT03676751 Comparator | Oct 2019 → Jul 2020 | — | University of California, San Francisco | Completed | No outcome recorded |
| Phase 4 | NCT03953118 Comparator | Sep 2019 → Jul 2021 | dry eye syndrome, mixed anxiety and depressive disorder, neuropathy, painful | University of California, San Francisco | Terminated | No outcome recorded |
| Phase 4 | NCT03676764 Comparator | Aug 2019 → Dec 2023 | — | University of California, San Francisco | Completed | No outcome recorded |
| Phase 4 | NCT03165123 Comparator | Jun 2019 → Jun 2020 | — | Assiut University | Unknown | No outcome recorded |
| Phase 4 | NCT04278937 Comparator | Apr 2019 → Feb 2020 | — | Ain Shams Maternity Hospital | Completed | No outcome recorded |
| Phase 4 | NCT03682653 Comparator | Apr 2019 → May 2022 | — | University of California, San Francisco | Completed | No outcome recorded |
| Phase 4 | NCT04062175 Comparator | Mar → Jun 2019 | infectious disease with sepsis | Ain Shams University | Completed | No outcome recorded |
| Phase 4 | NCT03532464 Comparator | Oct 2018 → Aug 2020 | chlamydia trachomatis infectious disease, infective vaginitis | University Hospital, Bordeaux | Completed | No outcome recorded |
| Phase 4 | NCT03220074 Background | Dec 2017 → Jun 2021 | mycobacterial infectious disease | Mahidol University | Completed | No outcome recorded |
| Phase 4 | NCT03338244 Comparator | Oct 2017 → Jul 2020 | — | University of California, San Francisco | Completed | No outcome recorded |
| Phase 4 | NCT03273296 Comparator | Oct → Dec 2017 | — | Finnish Institute for Health and Welfare | Completed | No outcome recorded |
| Phase 4 | NCT03083197 Comparator | Oct 2017 → Oct 2026 expected | scrub typhus | University of Oxford | Active not recruiting | No outcome recorded |
| Phase 4 | NCT03187834 Comparator | Jul → Sep 2017 | — | University of California, San Francisco | Completed | No outcome recorded |
| Phase 4 | NCT02677701 Comparator | Oct 2016 → Feb 2020 | cystic fibrosis | Seattle Children's Hospital | Completed | No outcome recorded |
| Phase 4 | NCT03233880 Comparator | Jul 2016 → Aug 2018 | preeclampsia | Ain Shams Maternity Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT02913118 Background | Jul 2016 → Jan 2019 | — | Qingfeng Pharmaceutical Group | Unknown | No outcome recorded |
| Phase 4 | NCT02047981 Comparator | Dec 2014 → Sep 2018 | — | University of California, San Francisco | Completed | No outcome recorded |
| Phase 4 | NCT02307825 Comparator | Nov 2014 → Aug 2017 | chronic rhinosinusitis | University of Montreal Hospital Centre (CHUM) | Completed | No outcome recorded |
| Phase 4 | NCT02048007 Comparator | Nov 2014 → Aug 2020 | — | University of California, San Francisco | Completed | No outcome recorded |
| Phase 4 | NCT01825408 Comparator | Feb 2013 → Jun 2014 | sinusitis | University of North Carolina, Chapel Hill | Completed | No outcome recorded |
| Phase 4 | NCT01820026 Background | Dec 2012 → May 2015 | cirrhosis of liver | University of Roma La Sapienza | Unknown | No outcome recorded |
| Phase 4 | NCT01721616 Comparator | Nov 2012 → Nov 2014 | endometritis | University of Missouri, Kansas City | Withdrawn | No outcome recorded |
| Phase 4 | NCT01469702 Background | Dec 2011 → Aug 2012 | cat-scratch disease | Tel-Aviv Sourasky Medical Center | Unknown | No outcome recorded |
| Phase 4 | NCT02107274 Comparator | Nov 2011 → Dec 2013 | bronchiectasis | Penang Hospital, Malaysia | Completed | No outcome recorded |
| Phase 4 | NCT05299567 Comparator | Aug 2010 → Jul 2011 | postinfectious bronchiolitis obliterans | Claudio Castanos | Completed | No outcome recorded |
| Phase 4 | NCT01661985 Comparator | Feb 2010 → Aug 2015 | Mycoplasmoides infection, cervicitis, chlamydia trachomatis infectious disease, urethritis | Ostergotland County Council, Sweden | Unknown | No outcome recorded |
| Phase 4 | NCT00803452 Comparator | Jul 2008 → Dec 2010 | blepharitis | University of Louisville | Completed | No outcome recorded |
| Phase 4 | NCT00792922 Comparator | May 2008 → Jun 2013 | trachoma | Johns Hopkins University | Completed | No outcome recorded |
| Phase 4 | NCT00575367 Comparator | Mar → Oct 2008 | bacterial infectious disease, eye infectious disorder | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 4 | NCT00575380 Comparator | Dec 2007 → Jun 2008 | bacterial infectious disease, cataract, eye infectious disorder | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 4 | NCT00431964 Comparator | Feb 2007 → Jul 2009 | cystic fibrosis | CF Therapeutics Development Network Coordinating Center | Completed | No outcome recorded |
| Phase 4 | NCT00245440 Comparator | Dec 2005 → Jul 2006 | maxillary sinusitis | CPL Associates | Terminated | No outcome recorded |
| Phase 4 | NCT00245453 Comparator | Oct 2005 → Jul 2006 | bacterial pneumonia, chronic bronchitis | CPL Associates | Withdrawn | No outcome recorded |
| Phase 4 | NCT00645112 Comparator | Nov 2003 → Jan 2004 | otitis media | Abbott | Completed | No outcome recorded |
| Phase 4 | NCT00644774 Comparator | Jan 2003 | — | Abbott | Completed | No outcome recorded |
| Phase 4 | NCT00347776 Comparator | Aug 2001 → Dec 2003 | eyelid disorder | Johns Hopkins University | Completed | No outcome recorded |
| Phase not applicable32 trials | ||||||
| — | NCT07585461 Comparator | Apr 2026 → Dec 2028 expected | AIDS-related disorder, Mycobacterium avium complex disease | Shanghai Public Health Clinical Center | Not yet recruiting | No outcome recorded |
| — | NCT06906757 Comparator | Sep 2025 → Dec 2029 expected | preterm premature rupture of the membranes | University of Melbourne | Not yet recruiting | No outcome recorded |
| — | NCT06325293 Comparator | Jan 2025 → Nov 2028 expected | Mycoplasma pneumoniae pneumonia | Christoph Berger | Recruiting | No outcome recorded |
| — | NCT07148622 Comparator | Oct 2024 → Aug 2025 | preterm premature rupture of the membranes | Yuzuncu Yil University | Completed | No outcome recorded |
| — | NCT06207786 Background | Sep 2024 → May 2029 | epidermal appendage tumor, skin cancer | Mayo Clinic | Withdrawn | No outcome recorded |
| — | NCT06141330 Background | Feb 2024 → Feb 2025 | acne | HITEC-Institute of Medical Sciences | Completed | No outcome recorded |
| — | NCT05949190 Background | Aug 2023 → Oct 2026 expected | postpartum depression | Washington University School of Medicine | Active not recruiting | No outcome recorded |
| — | NCT05847322 Background | Dec 2022 → Dec 2026 expected | — | University of Southampton | Recruiting | No outcome recorded |
| — | NCT07064278 Background | Dec 2022 → May 2024 | Mycoplasma pneumoniae pneumonia | Children's Hospital of Hebei Province | Completed | No outcome recorded |
| — | NCT04463420 Background | Aug → Nov 2020 | COVID-19 | Baqiyatallah Medical Sciences University | Unknown | No outcome recorded |
| — | NCT04871633 Background | Aug → Nov 2020 | COVID-19 | King Edward Medical University | Completed | No outcome recorded |
| — | NCT04296383 Comparator | Jun 2020 → Aug 2021 | Mycoplasma pneumoniae pneumonia | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | Unknown | No outcome recorded |
| — | NCT04380818 Background | Jun 2020 → Sep 2021 | viral pneumonia | Grupo de Investigación Clínica en Oncología Radioterapia | Unknown | No outcome recorded |
| — | NCT04394182 Background | Apr → Dec 2020 | cytokine release syndrome, viral pneumonia | Fundacion GenesisCare | Suspended | No outcome recorded |
| — | NCT04441424 Background | Apr → Jun 2020 | — | Alkarkh Health Directorate-Baghdad | Completed | No outcome recorded |
| — | NCT04622891 Comparator | Apr → Jul 2020 | COVID-19 | South Valley University | Completed | No outcome recorded |
| — | NCT03944317 Comparator | Jun → Nov 2019 | malaria, pregnancy disorder | Federal Medical Centre, Owo | Unknown | No outcome recorded |
| — | NCT03831269 Comparator | Feb 2019 → Jun 2020 | pityriasis lichenoides | Cairo University | Unknown | No outcome recorded |
| — | NCT03530319 Comparator | Nov 2018 → Dec 2021 | Mycoplasma pneumoniae pneumonia | National Taiwan University Hospital | Unknown | No outcome recorded |
| — | NCT03911440 Comparator | Nov 2018 → Dec 2022 | Mycoplasma pneumoniae pneumonia | National Taiwan University Hospital | Unknown | No outcome recorded |
| — | NCT02756403 Comparator | Mar 2016 → Jul 2017 | — | Medstar Health Research Institute | Completed | No outcome recorded |
| — | NCT02173145 Comparator | Aug 2014 → Aug 2019 | idiopathic pulmonary fibrosis | Insel Gruppe AG, University Hospital Bern | Completed | No outcome recorded |
| — | NCT02362906 Background | Apr 2014 → Aug 2015 | pneumonia | Liaoning University of Traditional Chinese Medicine | Unknown | No outcome recorded |
| — | NCT01154569 Comparator | Jun 2010 → Jul 2011 | — | University of Alberta | Completed | No outcome recorded |
| — | NCT00985244 Comparator | May 2010 → Jun 2013 | chronic obstructive pulmonary disease | R.S. Djamin | Completed | No outcome recorded |
| — | NCT01008761 Comparator | Jan 2010 → Dec 2012 | asthma | Janielee Williamson | Unknown | No outcome recorded |
| — | NCT00944515 Comparator | Aug 2009 → Dec 2015 | sinusitis | Mahidol University | Completed | No outcome recorded |
| — | NCT01217099 Comparator | May 2007 → May 2010 | Mycoplasma pneumoniae pneumonia | Chongqing Medical University | Terminated | No outcome recorded |
| — | NCT00644150 Background | Apr 2007 → Jul 2011 | HIV infectious disease, chlamydia infectious disease, gonorrhea | University of California, Los Angeles | Completed | No outcome recorded |
| — | NCT01463371 Comparator | Oct 2006 → Apr 2007 | bronchiectasis | La Fe Health Research Institute | Completed | No outcome recorded |
| — | NCT00325897 Comparator | Mar 2006 → Jun 2010 | chronic obstructive pulmonary disease | University of Minnesota | Completed | No outcome recorded |
| — | NCT00001128 Background | ? → Jun 2005 | HIV infectious disease, cryptosporidiosis | National Institute of Allergy and Infectious Diseases (NIAID) | Terminated | No outcome recorded |
Press releases naming this drug 5 releases
| Date | Issuer | Release |
|---|---|---|
| 2018-06-12 | Pfizer | Pfizer Announces Extension of Zithromax® Antibiotic Donation Program through 2025 to Help Eliminate World’s Leading Infectious Cause of Blindness pfizer.com ↗ |
| 2015-11-15 | Pfizer | Global Partners Announce Donation of 500 Millionth Dose of Azithromycin, Marking Exceptional Progress to Help Alleviate the Suffering from Trachoma pfizer.com ↗ |
| 2006-11-21 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Agreement With Pfizer Regarding Idarubicin, Azithromycin, And Epirubicin tevapharm.com ↗ |
| 2006-02-09 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Comments on Pfizer Press Release Regarding Azithromycin tevapharm.com ↗ |
| 2005-11-14 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Approval of Azithromycin Tablets tevapharm.com ↗ |
Evidence & citations 39 cited values
Every value below carries the sentence it was read from. 595 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZITHROMYCIN | “Bacterial or Viral infection treatment may include: Doxycycline, Minocycline, Nitazoxanide, Hydroxychloroquine, Rifampin, Dapsone, Azithromycin, Tetracycline, Benzathine...” NCT05894954 ↗570“This is a non inferiority test aimed to compare the efficacy and safety in add on to Azithromycin, an antimalarial drug, a treatment combination of the antimalrial drug with an...” NCT04502342 ↗ “Group 2 will receive azithromycin 500 mg once daily (od) (Truxa®, Laboratorios Monte Verde SA, Argentina), levofloxacin 500 mg od (Laboratorios Asofarma de México SA de CV,...” NCT02726269 ↗ “This standard treatment is personalized according to the severity but is not limited to standard antiviral therapy, azithromycin 500 mg a day, vitamin C 500 mg 8 hourly a day,...” NCT05398965 ↗ “Patients receiving azithromycin for prophylaxis or treatment of BOS, must be on a stable regimen for a least 4-weeks prior to randomization and will continue to receive...” NCT03657342 ↗ “Anti-STI regimen: ciprofloxacin 500mg orally, doxycycline 100mg BID orally 7 days and metronidazole 2g orally (cefuroxime im and/or azithromycin alternatively for pregnant and...” NCT00713999 ↗ “azithromycin (Zithromax) pediatric suspension formulation (200 mg/5 ml) administered as an oral suspension at a dose of 20 mg/kg once a day (maximal dose 500 mg/day) for 3...” NCT00643539 ↗ “This randomized add-on open clinical study evaluated the short-term effects of azithromycin (Az) as an adjunct to scaling and root planing (SRP) in patients with chronic periodontitis.” NCT05506371 ↗ “Current guidelines recommend a macrolide-based triple therapy consisting of a macrolide (azithromycin or clarithromycin), ethambutol, and a rifamycin (typically rifabutin).” NCT07585461 ↗ “One of seven antibiotics (amoxicillin; amoxicillin/clavulanate potassium; azithromycin; cefaclor; cephalexin; cefdinir; or clindamycin) will be given at standard dosage” NCT01561703 ↗ “Group 1: Azithromycin 500 mg per day, three days a week plus oral levamisole 150 mg per day, two days a week. Group 2: Azithromycin 500 mg per day, three days a week.” NCT01348321 ↗ “combination of two pharmaceutical drugs, Azithromycin (AZIT) and Ivermectin (IVER) administered orally in the treatment of head lice infestations.” NCT03578679 ↗ “The regimen consists of Omeprazole (20 mg/BD)+ Amoxicillin (1 g/day)+ Bismuth subcitrate (240 mg/BD)+ Azithromycin (500 mg/BD)for two weeks” NCT01759628 ↗ “The regimen consists of Omeprazole (20 mg/BD)+ Amoxicillin (1 g/day)+ Bismuth subcitrate (240 mg/BD)+ Azithromycin (500 mg/BD)for two weeks” NCT01712711 ↗ “Second group will receive 250 mg of azithromycin per day for a period of 5 days, after an initial dose of 500 mg one hour before NSPT.” NCT06199440 ↗ “administration of Azithromycin (AZM) during acute, Respiratory Syncytial Virus (RSV)-induced respiratory failure will be beneficial” NCT05026749 ↗ “Study treatments of oseltamivir and azithromycin (500 mg/day), or oseltamivir alone, both for 5 days, were allocated at 1:1 ratio.” PMID 28535933 ↗ May 2017 “The group I received Sofosbuvir plus Ledipasvir and Group II received Oseltamivir, hydroxychloroquine "HCQ" plus Azithromycin.” NCT04530422 ↗ “One group will receive Cefazolin 1gm intravenous + Azithromycin 500mg intravenous 30-60 minutes prior to incision.” NCT00805545 ↗ “If patients are allergic to ceftriaxone, they will be treated with azithromycin (2 g single oral dose).” NCT00644150 ↗ “Subjects will receive either Hydroxychloroquine with Azithromycin or Hydroxychloroquine with Sirolimus” NCT04374903 ↗ “Omeprazole (20 mg/BD)+ Amoxicillin (1 g/day)+ Bismuth subcitrate (240 mg/BD)+ Azithromycin (500 mg/BD)” NCT01654549 ↗ “oral quinolone (ciprofloxacin or levofloxacin) or oral macrolide (azithromycin or clarithromycin)” NCT03220074 ↗ “Receive azithromycin 500 mg iv daily for 48 hours followed by 500 mg orally (pills) for 5 days.” NCT05328817 ↗ “To date, these therapies may include remdesivir, chloroquine, hydroxychloroquine, azithromycin.” NCT04395170 ↗ “Azithromycin 500 mg, once daily (for those persons who are allergic to fluoroquinolones);” NCT04150250 ↗ “Safety and Efficacy Pilot Study of AzaSite® (Azithromycin) in Subjects With Blepharitis” NCT00629980 ↗ “Safety and Efficacy Pilot Study of AzaSite (Azithromycin) in Subjects With Blepharitis” NCT00629590 ↗ “Azithromycin: 500 mg as a loading dose (Day 1) followed by 250 mg o.d. Day 2 - Day 5” NCT04358081 ↗ “Day 1: Oral Azithromycin 1 g once and intravenous Ampicillin 2 g every 6 hours” NCT06917157 ↗ “azithromycin 500mg po tiw (250mg po tiw if weight below 50kg) for 6 months.” NCT07084402 ↗ “500 mg azithromycin on the first day and 250 mg on the second to fifth days” NCT04463420 ↗ “Azithromycin 500 mg first day, followed by 250 mg /d 4 days (oral or EV)” NCT04374539 ↗ “400 mg po cefixime plus 1 gram azithromycin po under direct observation” NCT06468462 ↗ “Individuals received either azithromycin or amoxicillin for 3 or 7 days” NCT05169255 ↗ “Azithromycin 250-500 mg plus ethambutol HCl 15 mg/kg orally once daily.” NCT04553406 ↗ “Oral Azithromycin , Cetirizine, Paracetamol, Zinc, Vitamin C, Vitamin D” NCT04935515 ↗ “1 gm Azithromycin orally, provided as four 250 mg tablets for adults” NCT00618449 ↗ “AZITHROMYCIN Pfizer cpr pell 500mg, Pfizer PFE Switzerland GmbH” NCT04669717 ↗ “Solumedrol, dexamethasone,prednisolone, azithromycin” NCT04871633 ↗ “Azithromycin or erythromycin may be added as well.” NCT02605122 ↗ “Azithromycin 1g per os once at months 1, 4 and 7” NCT01329588 ↗ “azithromycin (Azasite) ophthalmic solution (1%)” PMID 21138337 ↗ Dec 2010 “systemic azithromycin 500 mg per day for 3 days” NCT06715150 ↗ “AzaSite® (Azithromycin Ophthalmic Solution) 1%” NCT00629941 ↗ “clarithromycin, azithromycin and thioacetazone” NCT03237182 ↗ “The preferred IV macrolide is azithromycin” NCT02735707 ↗ “SHB001, an azithromycin dermal formulation” NCT01243008 ↗ “Oral Azithromycin 250 - 500mg Once daily” NCT07485010 ↗ “Fluticasone propionate (FP),Azithromycin” NCT04527016 ↗ “ceftriaxone and azithromycin capsules” NCT04461925 ↗ “1% azithromycin in DuraSite (AzaSite” PMID 17652708 ↗ Aug 2007 “Azithromycin 250mg/day for 5 days” NCT04591600 ↗ “Azithromycin/clarithromycin” NCT06207786 ↗ “Azithromycin=Zithromax” NCT01074554 ↗ “B - Azithromycin” NCT00682656 ↗ “Azithromycin*” NCT02099240 ↗ |
| Known as | Azasite | “A Single-Center, Open-Label, Randomized Pilot Study of the Safety and Efficacy of AzaSite® Ophthalmic Solution, 1% in Combination With Mechanical Therapy Versus Mechanical...” NCT00629590 ↗8“Safety and Efficacy Pilot Study of AzaSite® (Azithromycin) in Subjects With Blepharitis” NCT00629980 ↗ “azithromycin (Azasite) ophthalmic solution (1%)” PMID 21138337 ↗ Dec 2010 “AzaSite (azithromycin ophthalmic solution)” NCT00575367 ↗ “1% azithromycin in DuraSite (AzaSite” PMID 17652708 ↗ Aug 2007 |
| Known as | AzaSite (azithromycin ophthalmic solution) | “AzaSite (azithromycin ophthalmic solution)” NCT00575380 ↗ |
| Known as | AZI | “The current principle of yaws eradication (the Morges strategy) is based on single round mass drug administration (MDA) of azithromycin (AZI) called total community treatment...” NCT03490123 ↗7“The purpose of this study is to assess the efficacy of 3 days of azithromycin (AZI) compared to 3 days of ciprofloxacin (CIP) (standard-of-care) for the treatment of children...” NCT03854929 ↗ “Azithromycin (AZI) is a macrolide antibiotic but does not have the mentioned druf interactions , has fewer gastrointestinal side effects, and fewer risks of QT prolongation and...” NCT01323582 ↗ “efficacy and safety of azithromycin (AZI) mass drug administration (MDA) to 1-11-month-old infants” PMID 37968741 ↗ Nov 2023 “Azithromycin (AZI) is used for its antibiotic and antimalarial properties in pregnancy.” PMID 26711756 ↗ Dec 2015 “azithromycin (AZI) plus piperaquine (PQ) given as IPTp” NCT02575755 ↗ “Azithromycin (AZI), a broad-spectrum antibiotic” PMID 23629714 ↗ Apr 2013 “azithromycin (AZI) in a malaria-endemic area” PMID 34479861 ↗ Sep 2021 |
| Known as | AZICINE | “Each sachet AZICINE of 1.5 g powder contains: 250mg of Azithromycin dihydrate, dissolved in warm water, dosed to 10mg/kg body weight /daily/ 3 days” NCT03854929 ↗ |
| Known as | AZIT | “combination of two pharmaceutical drugs, Azithromycin (AZIT) and Ivermectin (IVER) administered orally in the treatment of head lice infestations.” NCT03578679 ↗ |
| Known as | Azithro | “Azithromycin (Azithro)” NCT07625228 ↗ |
| Known as | Azithromcyin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07485010 ↗ |
| Known as | Azithromycin Dihydrate | “Zithromax (Azithromycin Dihydrate) 600mg Tablets Pfizer Inc.” NCT00866216 ↗1“Zithromax (azithromycin dihydrate) 600 mg Tablets” NCT00865670 ↗ |
| Known as | Azithromycin Extended Release | “Zmax (Azithromycin Extended Release)” NCT00367120 ↗ |
| Known as | azithromycin immediate release | “azithromycin immediate release (Zithromax)” NCT00644176 ↗ |
| Known as | Azithromycin Injection | “Drug: Azithromycin Injection” NCT06605118 ↗ |
| Known as | Azithromycin monohydrate | “Azithromycin monohydrate is a macrolide antibacterial drug, FDA-approved in the US for the treatment of Chlamydia trachomatis (CT) in dose 1 gram (4 capsules of 250 mg),...” NCT03608774 ↗ |
| Known as | Azithromycin Pfizer | “Azithromycin Pfizer® powder for oral suspension will be used in the active comparator arm” NCT06325293 ↗ |
| Known as | Azithromycin SR | “A Multicenter, Randomized, Double-Blind, Double-Dummy Trial of Azithromycin SR Compared With Levofloxacin for the Treatment of Mild to Moderate Pneumonia in Adult Patients” NCT00643734 ↗1“Azithromycin SR (Microspheres Formulation)” NCT00254566 ↗ |
| Known as | azithromycin sustained release | “The study was performed to see if a single, 2.0-g oral dose of azithromycin sustained release (SR) was at least as effective as a 7-day regimen of levofloxacin (500 mg once...” NCT00643734 ↗ |
| Known as | Azithromycin Tablets | “Drug: Azithromycin Tablets” NCT04454151 ↗ |
| Known as | Azithromycin=Zithromax | “Azithromycin=Zithromax” NCT01074554 ↗1“Azithromycin/Zithromax” NCT01561703 ↗ |
| Known as | Azithromycine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06349122 ↗ |
| Known as | AZM | “A single oral dose of azithromycin (AZM) given during labor to women planning a vaginal delivery reduced maternal infections including sepsis, with a stronger effect in...” PMID 41527950 ↗ Jan 20266“AIM: To evaluate the effects of systemic azithromycin (AZM) as an adjunct to scaling and root planing (SRP) in the treatment of generalized chronic periodontitis (ChP).” PMID 21770996 ↗ Jul 2011 “Therefore azithromycin (AZM) is an antibiotic known to have an antiviral effect but also which has anti-inflammatory activity in addition to its antimicrobial effect.” NCT04371107 ↗ “This study was undertaken to prospectively evaluate the effect of long-term azithromycin (AZM) on radiological features in patients with bronchiectasis.” PMID 34974413 ↗ Dec 2021 “administration of Azithromycin (AZM) during acute, Respiratory Syncytial Virus (RSV)-induced respiratory failure will be beneficial” NCT05026749 ↗ “Participants received a once-weekly weight-based dose of 1-5 tablets of azithromycin (AZM: 250mg) or placebo, taken orally.” PMID 35704559 ↗ Jun 2022 “single-dose oral azithromycin (AZM) 20 mg/kg” NCT00356720 ↗ |
| Known as | Azrolid | “combined antibiotic chemotherapy azithromycin(Azrolid) 1 gm single oral dose 2 hours before cesarean delivery” NCT04062175 ↗ |
| Known as | AZT | “This is an exploratory, open label, multi-center study to evaluate the efficacy of hydroxychloroquine (HCQ) (400 mg BID on D1 and 400 mg/day on D2 to D5) and azithromycin (AZT)...” NCT04329572 ↗1“Azithromycin (AZT) placebo o.d.” NCT04358081 ↗ |
| Known as | azythromycin | “By contrast, azythromycin, a bacteriostatic antibiotic of the macrolides family blocking the protein synthesis in bacteria, has a strong inhibitory effect on Stx production and...” NCT02336516 ↗ |
| Known as | Bicillin L-A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00427609 ↗ |
| Known as | COMMON BRAND(S): Zithromax GENERIC NAME(S): Azithromycin | “COMMON BRAND(S): Zithromax GENERIC NAME(S): Azithromycin” NCT04341727 ↗ |
| Known as | CP-62,993 | “azithromycin SR (Zithromax; compound: CP-62,993)” NCT00643409 ↗1“azithromycin SR (Zithromax; compound: CP-62,993)” NCT00644449 ↗ |
| Known as | SHB001 | “SHB001, an azithromycin dermal formulation” NCT01243008 ↗ |
| Known as | T1225 | “Azithromycin (T1225)” NCT00357383 ↗3“Azithromycin (T1225)” NCT00357292 ↗ “Azithromycin (T1225)” NCT00357539 ↗ “Azithromycin (T1225)” NCT00357773 ↗ |
| Known as | Xithrone | “Azithromycin 1Gm orally, single dose (Xithrone 500 mg two tablets, Amoun, Inc, Cairo, Egypt) Group (A) OR” NCT03233880 ↗1“nebulized azithromycin (Xithrone, Amoun, Egypt)” NCT06584474 ↗ |
| Known as | Zithromax | “Comparative, Randomized, Single-Dose, 2-way Crossover Bioavailability Study of Geneva 600 mg Azithromycin Monohydrate Tablets and Pfizer Inc. (Zithromax) 600 mg Azithromycin...” NCT00865670 ↗29“Participants will use azithromycin (Zithromax) 500mg three times a week (10mg.kg for participants under 50Kg) which can be dropped to 250 mg three times a week for dose related...” NCT06272370 ↗ “azithromycin (Zithromax) pediatric suspension formulation (200 mg/5 ml) administered as an oral suspension at a dose of 20 mg/kg once a day (maximal dose 500 mg/day) for 3...” NCT00643539 ↗ “The intravenous (IV) regimen containing azithromycin (Zithromax) plus ampicillin-sulbactam is consistent with current guidelines for the treatment of CAP.” NCT00137007 ↗ “Zithromax® for oral suspension is supplied in bottles containing azithromycin dehydrate powder equivalent to 1200mg per bottle” NCT03676751 ↗ “ZITHROMAX ® 40mg/ml solution. DCI : Azithromycin . Pfizer ® 20mg/kg dose with a maximum dose of 500mg per day for three days” NCT02336516 ↗ “treated with either Ketek® Telithromycin Once Daily for 7 Days, or Zithromax® Azithromycin Once Daily for 5 Days” NCT00237445 ↗ “azithromycin (Zithromax®) was donated by Pfizer via the International Trachoma Initiative (ITI).” PMID 37152362 ↗ Apr 2023 “Azithromycin capsule (Zithromax, Pfizer) (250 mg / 12hrs on empty stomach for 3 days)(Group 1).” NCT05118984 ↗ “Group 1 of 15 subjects: 2 g AZ (Zithromax) plus 300 mg CQ base weekly for 6 weeks” NCT03278808 ↗ “Exploratory study of a novel "oleogel" dosage form of Azithromycin (Zithromax)” NCT05796362 ↗ “Azithromycin (ZITHROMAX®), 500mg on D1 and then 250mg/d for the next 4 days” NCT04371406 ↗ “Mylan's azithromycin 600 mg tablets to Pfizer's Zithromax® 600 mg tablets” NCT00649935 ↗ “the commercially available azithromycin (Zithromax®, Pfizer, Inc.)” NCT00834756 ↗ “a single Per Os administration of Zithromax® (Azithromycin 1g)” NCT00356772 ↗ “commercially available azithromycin (Zithromax®, Pfizer, Inc.)” NCT00834132 ↗ “Zithromax (azithromycin for oral suspension) 200mg/5mL Pfizer” NCT00875966 ↗ “Zithromax (Azithromycin Dihydrate) 600mg Tablets Pfizer Inc.” NCT00866216 ↗ “Azithromycin, also known as Zithromax or Zmax or Zpak” NCT04374552 ↗ “azithromycin SR (Zithromax; compound: CP-62,993)” NCT00644449 ↗ “azithromycin SR (Zithromax; compound: CP-62,993)” NCT00643409 ↗ “azithromycin immediate release (Zithromax)” NCT00644176 ↗ “Azithromycin Injection [Zithromax]” NCT05647993 ↗ “azithromycin (Zithromax)” NCT00648726 ↗ “azithromycin (Zithromax)” NCT00644293 ↗ |
| Known as | Zithromax (Zimexir, Exir, Brojerd, Iran) | “Zithromax (Zimexir, Exir, Brojerd, Iran)” NCT01921738 ↗ |
| Known as | Zithromax™ | “Zithromax™ (azithromycin) 500mg tablets” NCT00232154 ↗ |
| Known as | Zitromax (Azithromycin Dihydrate, Pfizer, ZTM250) | “Zitromax (Azithromycin Dihydrate, Pfizer, ZTM250)” NCT01009619 ↗ |
| Known as | ZMAX | “Azithromycin, also known as Zithromax or Zmax or Zpak” NCT04374552 ↗1“Zmax (Azithromycin Extended Release)” NCT00367120 ↗ |
| Known as | Zpak | “Azithromycin, also known as Zithromax or Zmax or Zpak” NCT04374552 ↗ |
| Action | Inhibit | “the ability of azithromycin to inhibit alginate-production” NCT00411736 ↗ |
| Modality | Small molecule | “macrolide antibiotics” NCT00001023 ↗ |
| Route | Oral | “600 milligrams orally once a week” NCT00000617 ↗ |
| Target | CYP3A4 | “Azithromycin is a possible weak to moderate inhibitor of CYP3A4” NCT00983294 ↗ |